160 related articles for article (PubMed ID: 36089725)
1. Hearing Loss After the First Low Dose Administration of Cisplatin.
Yildirim A; Fidan E; Ozdemir F
J Coll Physicians Surg Pak; 2022 Sep; 32(9):1216-1218. PubMed ID: 36089725
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
3. Long-term auditory follow-up in the management of pediatric platinum-induced ototoxicity.
Fetoni AR; Brigato F; De Corso E; Lucidi D; Sergi B; Scarano E; Galli J; Ruggiero A
Eur Arch Otorhinolaryngol; 2022 Oct; 279(10):4677-4686. PubMed ID: 35024956
[TBL] [Abstract][Full Text] [Related]
4. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
5. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
Tan WJT; Vlajkovic SM
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003734
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
Tang Q; Wang X; Jin H; Mi Y; Liu L; Dong M; Chen Y; Zou Z
Eur J Pharm Biopharm; 2021 Jun; 163():60-71. PubMed ID: 33775853
[TBL] [Abstract][Full Text] [Related]
8. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb SJ; Martin K; Abab J; Ratcliffe I; Thornton R; Lineton B; Ellis M; Moody R; Stanton L; Galanopoulou A; Maishman T; Geldart T; Bayne M; Davies J; Lamb C; Popat S; Joffe JK; Nutting C; Chester J; Hartley A; Thomas G; Ottensmeier C; Huddart R; King E
Eur J Cancer; 2017 Dec; 87():75-83. PubMed ID: 29128692
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
10. Protective role of misoprostol against cisplatin-induced ototoxicity.
Doğan M; Polat H; Yaşar M; Kaya A; Bayram A; Şenel F; Özcan İ
Eur Arch Otorhinolaryngol; 2016 Nov; 273(11):3685-3692. PubMed ID: 27052552
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy.
Sanchez VA; Dinh PC; Rooker J; Monahan PO; Althouse SK; Fung C; Sesso HD; Einhorn LH; Dolan ME; Frisina RD; Travis LB
J Cancer Surviv; 2023 Feb; 17(1):27-39. PubMed ID: 36637632
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
Stöhr W; Langer T; Kremers A; Bielack S; Lamprecht-Dinnesen A; Frey E; Beck JD;
Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
Paken J; Govender CD; Pillay M; Feyasa M; Sewram V
PLoS One; 2023; 18(4):e0283639. PubMed ID: 37014872
[TBL] [Abstract][Full Text] [Related]
15. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced ototoxicity: transporters playing a role in cisplatin toxicity.
Waissbluth S; Daniel SJ
Hear Res; 2013 May; 299():37-45. PubMed ID: 23467171
[TBL] [Abstract][Full Text] [Related]
17. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
Waissbluth S; Peleva E; Daniel SJ
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
[TBL] [Abstract][Full Text] [Related]
18. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
19. Recovery from cisplatin-induced ototoxicity: a case report and review.
Truong MT; Winzelberg J; Chang KW
Int J Pediatr Otorhinolaryngol; 2007 Oct; 71(10):1631-8. PubMed ID: 17706797
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of hearing in children with solid tumors treated by chemotherapy].
Gryczyńska D; Rychwalska M; Pekacka K; Krawczyński M; Bodalski J
Otolaryngol Pol; 2001; 55(2):179-83. PubMed ID: 11494735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]